EXACTLY! people have no clue what they are talking about, but they can teach the CEO how to run a Biotech company! ADXs has so may irons in a fire and are being in a forefront of cancer science and research with a great potential.
As to AXAL, it is more effective than SOC (38% vs 30%) with insignificant side effect vs SOC with heavy side effects. Just based on GOG P2 results AXAL could be already approved and that is why ADXS will get early EU approval. It is a great company with a GREAT future. the current price is a gift and when it starts going, it has a potential to be 7-8 times bagger in the making in a mid time.
Market Data 
Markets 
AI
